← Leaderboards
Marianna K Baum
Florida International University
$32,350,926
Attributed
$32,350,926
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $7.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,350,926 · 9
By mechanism
U01$19,202,768 · 3
R01$12,272,799 · 4
U54$875,359 · 1
R24$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantHiv InfectionsCohortZincClinical TrialsLiver DiseasesDrug AbuseLaboratoriesAlcoholsRecruitment ActivityOxidative StressBaseClinicSeleniumSubstance Abuse ProblemFutureRecording Of Previous EventsAnti-Retroviral AgentsUnited StatesPharmaceutical PreparationsFollow-UpMorbidity - Disease RateQuestionnairesAntioxidants
Grant awards (38)
Cohort Studies of HIV/AIDS and Substance Use in Miami$7,372,834
U01 · FY2025 · DA · contact PI
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase II$1,105,831
U01 · FY2023 · MD · contact PI
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations Phase II$1,105,562
U01 · FY2022 · MD · contact PI
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations$991,311
U01 · FY2022 · DA · contact PI
Community-Engaged Research on COVID-19 Testing Among Underserved and/or Vulnerable Populations$3,032,553
U01 · FY2020 · DA · contact PI
Cohort Studies on HIV/AIDS and Substance Abuse in Miami$1,077,827
U01 · FY2020 · DA · contact PI
Cohort Studies on HIV/AIDS and Substance Abuse in Miami$1,077,827
U01 · FY2019 · DA · contact PI
Cohort Studies on HIV/AIDS and Substance Abuse in Miami$1,077,827
U01 · FY2018 · DA · contact PI
Research Infrastructure Core$306,866
U54 · FY2018 · MD · contact PI
Cohort Studies on HIV/AIDS and Substance Abuse in Miami$1,077,827
U01 · FY2017 · DA · contact PI
Research Infrastructure Core$568,493
U54 · FY2017 · MD · contact PI
Cohort Studies on HIV/AIDS and Substance Abuse in Miami$166,800
U01 · FY2017 · DA · contact PI
Cohort Studies on HIV/AIDS and Substance Abuse in Miami$1,116,569
U01 · FY2015 · DA · contact PI
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease$444,941
R01 · FY2012 · AA · contact PI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants$637,960
R01 · FY2011 · DA · contact PI
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease$512,201
R01 · FY2011 · AA · contact PI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants$647,084
R01 · FY2010 · DA · contact PI
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease$529,279
R01 · FY2010 · AA · contact PI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants$630,622
R01 · FY2009 · DA · contact PI
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease$488,095
R01 · FY2009 · AA · contact PI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants$521,643
R01 · FY2008 · DA · contact PI
Alcohol & Antiretrovirals in HIV Infection, Oxidative Stress and Liver Disease$345,910
R01 · FY2008 · AA · contact PI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants$66,484
R01 · FY2008 · DA · contact PI
HIV Disease, Drug Abuse, & Nutrient Therapy in Botswana$675,825
R01 · FY2007 · DA · contact PI
HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants$438,830
R01 · FY2007 · DA · contact PI
HIV Disease, Drug Abuse, & Nutrient Therapy in Botswana$106,065
R01 · FY2007 · DA · contact PI
HIV Disease, Drug Abuse, & Nutrient Therapy in Botswana$798,689
R01 · FY2006 · DA · contact PI
HIV Disease, Drug Abuse, &Nutrient Therapy in Botswana$881,866
R01 · FY2005 · DA
Zinc Therapy in Zinc Deficient HIV+ Drug Users$487,484
R01 · FY2005 · DA
Zinc Therapy in Zinc Deficient HIV+ Drug Users$63,122
R01 · FY2005 · DA
HIV Disease, Drug Abuse, &Nutrient Therapy in Botswana$740,546
R01 · FY2004 · DA
Zinc Therapy in Zinc Deficient HIV+ Drug Users$689,598
R01 · FY2004 · DA
Zinc Therapy in Zinc Deficient HIV+ Drug Users$754,504
R01 · FY2003 · DA
HIV Disease, Drug Abuse, &Nutrient Therapy in Botswana$551,812
R01 · FY2003 · DA
Core--Research questions/feasibility and pilot projects$0
R24 · FY2003 · MD
Zinc Therapy in Zinc Deficient HIV+ Drug Users$700,317
R01 · FY2002 · DA
Zinc Therapy in Zinc Deficient HIV+ Drug Users$75,926
R01 · FY2002 · DA
Zinc Therapy in Zinc Deficient HIV+ Drug Users$483,996
R01 · FY2001 · DA